Philip Morris
Schering Plough New York Analysts' Meeting December 7, 1977
Fields
- Type
- NELE, NEWSLETTER
- Area
- WAKEHAM,HELMUT/KAROL SHARPE'S OFFICE
- Litigation
- Stmn/Produced
- Named Organization
- Cetus
- Schering Plough
- Site
- R37
- Master ID
- 1000229536/9811
Related Documents:- 1000229537-9544
- 1000229545-9550 Brief Synopsis
- 1000229551-9552 Introduction
- 1000229553-9555 Brief History of Cetus Financing
- 1000229556-9557
- 1000229558-9560 Special Note to Investors
- 1000229561-9563 Special Note Regarding Founder's Stock
- 1000229567-9569 Board of Directors
- 1000229575-9580 Achievements of Cetus People
- 1000229581-9599 Present Cetus Activities
- 1000229600-9616 Research Plan
- 1000229617-9619 Patents
- 1000229621-9656 Debenture Purchase Agreement
- 1000229657-9661 the Cetus Story
- 1000229663-9667 Cloning Business: It's Growing Fast It's Growing Fast
- 1000229668 World Roundup
- 1000229669-9670 Latin Drive: Brazil Spends Millions to Put Alcohol in Cars and Save Oil
- 1000229671 Can US Reduce Imports with Gasoline? Some Say Yes, But Officials Are Dubious
- 1000229672-9673 Bacterial Insulin Production Hears Reality
- 1000229674 Business World
- 1000229675-9677 Who Should Play God?
- 1000229679 Indiana Standard Labels Purchase Offer Part of Move to Wider Technology Base
- 1000229680 Big Deal for Berkley Bugs
- 1000229681 Oil-Less World May Run on Bugs
- 1000229682-9685 Tinkering with Life
- 1000229686-9687 Set for Biology's New Revolution
- 1000229688 Little Black Box of Cetus
- 1000229689-9695 Industry Is Finding More Jobs for Microbes
- 1000229696-9701 Dup of Id 1000229657-9661
- 1000229702-9710 Recombinant Molecular Research at Cetus Corporation
- 1000229711-9715 New Cetus Antibiotic
- 1000229716-9720 Letter to the Shareholders
- 1000229721-9726 Letter to Shareholders
- 1000229727-9728 Letters to the Shareholders
- 1000229729-9730
- 1000229731-9734 Letter to the Shareholders
- 1000229735-9736 Letter to Shareholders
- 1000229737-9749 the Manipulation of Genes
- 1000229750-9770 Microbial Genetics and the Future of the Pharmaceutical Industry
- 1000229771-9774 Recombinant Dna: Fact and Fiction
- 1000229775-9778 Testomony of Ronald E Cape, Phd President, Cetus Corporation, Berkeley, California Before the House Subcommittee on Science, Research and Technology
- 1000229779-9797 Biosystems Poised for Growth
- 1000229798-9805 Testimony of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkley, California Before the Senate Subcommittee on Science, Technology and Space
- 1000229806-9807 Statement of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkeley, California Before A Special Joint Congressional Hearing in Conjunction with Oversight Hearings on Science and Technology Policy the Senate Subcommittee on Science, Technology and Space of the Commerce, Science and Transportation Committee Presiding, Senator Adlai Stevenson, III Washington, Dc
- 1000229808-9811 Statement of Ronald E. Cape, Ph.D. President, Cetus Corporation, Berkeley, California at the Annual Meeting of the American Association for the Advancement of Science Session on Recombinant Dna Public Health and Biomedical Research Policy Washington, D.C.
- Named Person
- Bennett, R.J.
- Cave, J.B.
- Golby, R.W.
- Cave, J.B.
- Author (Organization)
- Blyth Eastman Dillion
- Request
- Stmn/R1-004
- Stmn/R1-150
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- ago74e00
Document Images
COMPIINY UPDATE
:
INVESTMENT RESEARCH
SCHERING-PLOUGH - NEW YORK ANALYSTS' MEETING, DECEMBER 7, 1977
management of Schering-Plough Corporation today. Representing management
(N.Y.S.E. Symbol - SGP - 30)
The two New York City health care splinter groups hosted a meeting for the
Ralph W. Golby, Vice President-Investor Relations. 2Sr. Bennett made brief
John B. Cave, Senior Vice President-Finance and-Administration, and Mr.
were Mr. Richard J. Bennett, President and Chief_Operating Officer, Z]r.
comments regarding Proventyl,.sisomicin and Gara.*nycin. A sumrnary of his
m
r
k
l
b
e
ar
s appears
ow:
e
.
work for the development of new products. We are attempting to learn more
possibilities, in that the company can also do additional strain mutation
of hope is being placed in this project. The "black box" has far reaching
of $6-8 million. Our sources inside the company tell us that a great deal
box" for improving yields that has been created in Kenilworth at an expense
company expects to do this work in-house. Mr.. Bennett discussed a "black
that the relationship with Cetus Corporation has now been severed, and the
million annually.with Cetus Corporation on this project. We'understand
to achieve yield improvements. Fie believe that Schering invested $1-2
working with Cetus Corporation, a California-based operation, in an attempt
would cover near term future needs in Europe. Schering-Plough has been
resulted from a decision that yield improvements in existing facilities
capacity. For example, the elimination of the proposed plant in Ireland
11. Fermentation yield improvements were characterized as "dramatic" in
recent years, reducing the company's need for additional manufacturing
about this project.
C~~ . . 1 . . . . - . . . . . .. . - :: .. -. . . . . ... , - . .. .. . ~.:.,.~;~, f.-~
1p3~ain Easlcnan Diilon &CO.
Yi=L~OI~fl~'aJ2t3/WortdHeadquarters:1221Arenueofthetimericas,NewYozk,N.Y.10020(212a 7305500 , i
